Preclinical research indicates that combining radiotherapy with PD-1/PD-L1 inhibitors may enhance anticancer activity by increasing interferon γ, tumor antigen cross-presentation, T-cell receptor clonality, PD-L1 expression, and reinvigorating TILs. Here, PDCD1 is linked to neoplasm.